Catalent Pharma Solutions, a global provider of drug development solutions and advanced delivery technologies, has acquired Relthy Laboratórios in Brazil. Catalent will expand its operations in Brazil, currently the sixth largest pharmaceutical market in the world, to provide customers in Latin America with access to drug delivery technologies. The deal will see Catalent further extend its presence in high growth, emerging markets, having recently announced its expansion into China with softgel and clinical trial supply operations.
Catalent has acquired 100% of the shares in the Indaiatuba-based, privately-held company. Founded in 1988, Relthy produces softgel encapsulated vitamin, mineral and supplement (VMS) products for the Brazilian market, but also supplies products in the prescription and over-the-counter (OTC) segments. It employs 350 and has a production capacity of around two billion capsules per annum.
Catalent will expand into the VMS nutritional market, while simultaneously expanding its primary and secondary packaging capabilities in the country. Relthy's management team will join Catalent and continue to play a leading role in driving Catalent's expanded capabilities and product development into the Brazilian market as well as expanding them into all other Latin American markets.
Relthy becomes Catalent's 11th softgel facility in its global network and will complement Catalent's existing pharmaceutical and OTC focused South American facilities, located in Sorocaba, Brazil and Buenos Aires, Argentina.
"This investment will benefit our domestic and international customers as it draws on both parties' complementary capabilities to holistically address market needs," said Dr. Aris Gennadios, president of softgel technologies, Catalent Pharma Solutions. "Brazil represents a key strategic location for Catalent and its customers, and this acquisition will create significant growth opportunities."
Financial terms were not disclosed.